Industry
Biotechnology
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 21, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 1:05 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 12:33 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 12:34 pm
Portfolio Pulse from Benzinga Newsdesk
April 12, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
April 11, 2024 | 6:23 am
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 8:49 pm
Portfolio Pulse from Benzinga Newsdesk
April 05, 2024 | 1:30 pm
Portfolio Pulse from Benzinga Newsdesk
February 07, 2024 | 2:28 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.